Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

F-star Therapeutics Shares Are Rallying Today - Read Why

  • invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ:FSTX) for $7.12 per share. 
  • The proposed acquisition values F-star at approximately $161 million. 
  • Just a year ago, F-star priced its IPO at $7.
  • F-star's next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharma's existing capabilities and reinforces its global oncology pipeline.
  • Four programs are progressing in the clinic, three based on F-star's tetravalent platform and one next-generation STING agonist, with multiple further undisclosed programs in development. 
  • Leveraging its modular antibody technology, F-star has forged collaborations with major international biopharma companies across a wide range of therapeutic areas, including oncology, immunology, and neurology.
  • Related: F-star Shares Rise On Bispecific Antibody Therapeutics Pact With Janssen.
  • The invoX and F-star Board of Directors have unanimously approved the transaction. It is expected to close in 2H of 2022.
  • invoX, established in 2021 in the U.K., is Sino Biopharma's international expansion platform, focusing on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics.
  • Price Action: FSTX shares are up 67.1% at $6.65 during the premarket session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.